lerapolturev
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2021 (NCT04690699)
Timeline
Indications
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06177964 | Phase 2 | Dec 31, 2023 | Duke University, Istari Oncology, Inc. |
| NCT04690699 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2021 | Istari Oncology, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Istari Oncology, Inc. | For profit | 2 | 1 | 1 | 2021 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1